HLS Therapeutics (TSE:HLS) Hits New 1-Year Low – Time to Sell?

HLS Therapeutics Inc. (TSE:HLS) shares hit a new 52-week low during trading on Friday. The company traded as low as C$3.51 and last traded at C$3.65, with a volume of 78,476 shares changing hands. The stock had previously closed at C$3.70.

Wall Street Analyst Weigh In

HLS has been the subject of a number of recent analyst reports. Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from C$7.00 to C$8.00 in a report on Friday, August 14th. Canaccord Genuity Group raised HLS Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Strong Buy” and a consensus price target of C$8.00.

HLS Therapeutics Stock Performance

The firm’s 50-day moving average price is C$4.11 and its 200 day moving average price is C$4.29. The company has a market cap of C$114.46 million, a price-to-earnings ratio of -13.70 and a beta of -0.52. The company has a current ratio of 1.05, a quick ratio of 1.01 and a debt-to-equity ratio of 75.86.

HLS Therapeutics (TSE:HLS) last released its earnings results on Thursday, November 12th. The company reported C($0.10) earnings per share (EPS) for the quarter. The company had revenue of C$20.15 million for the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. As a group, equities analysts expect that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.